# A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia

> **NCT07052006** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Halia Therapeutics, Inc.** · enrollment: 37 (actual)

## Conditions studied

- Myelodysplastic Syndrome
- Anemia in Myelodysplastic Syndromes

## Interventions

- **DRUG:** HT-6184

## Key facts

- **NCT ID:** NCT07052006
- **Lead sponsor:** Halia Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-09
- **Primary completion:** 2026-01-08
- **Final completion:** 2026-05-25
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07052006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07052006, "A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07052006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*